Surgeons report high satisfaction with Dexycu
Surgeons reported high satisfaction for themselves and their patients in a retrospective study of dexamethasone intraocular suspension 9%, according to a poster presented at the virtual Women in Ophthalmology Summer Symposium.
“Results show a strong anti-inflammatory effect with resolution of anterior chamber cell and flare postoperatively after cataract surgery,” author Cathleen M. McCabe, MD, told Healio/OSN.
Interim results of the “real-world” retrospective study included data from 332 eyes of 271 patients (mean age, 71.6 years) who underwent cataract surgery and were administered a single dose of Dexycu (EyePoint Pharmaceuticals) for inflammation control postoperatively.
Regarding safety, mean IOP was stable at postoperative day 30, and few adverse events were reported. One case of blurred vision was attributed to treatment, and two cases of corneal edema were possibly related to treatment.
“Patient and surgeon satisfaction was high, with greater than 90% who were satisfied or very satisfied with this treatment,” McCabe said.
A total of 91.3% of surgeons reported being “satisfied” or “very satisfied” with the treatment, and 79% rated the efficacy of the treatment “superior” to topical steroids.
Surgeons retrospectively reported their impression of each patient’s satisfaction with the treatment, and 90.6% of patients were reported to be “satisfied” or “very satisfied.”
Collapse
McCabe CM. Sustained-release dexamethasone intraocular suspension 9% for post-cataract inflammation control: Interim data from a retrospective study. Presented at: Women in Ophthalmology Summer Symposium; Aug. 21-23, 2020 (virtual meeting).
Read more about